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Abstract
Purpose: To evaluate the diagnostic performance of combining non-enhanced magnetic resonance imaging (MRI) 
and non-enhanced endoscopic ultrasonography (EUS) for assessing the malignant potential of lesions in patients 
with intraductal papillary mucinous neoplasms of the pancreas (IPMNs).
Material and methods: Data from 38 patients histopathologically diagnosed with IPMN adenomas or IPMN adenocar-
cinomas were retrospectively analysed. Preliminary univariate and multivariate analyses were conducted to identify 
statistically significant associations. Three blinded radiologists evaluated the image sets to assess the diagnostic 
performance of combined use of non-enhanced MRI and EUS as opposed to non-enhanced MRI alone in distin-
guishing malignant from benign lesions. Observer performance and interobserver variability were determined using 
receiver-operating-characteristic curve analysis and weighted κ statistics.
Results: Multivariate analyses identified a significant difference between the abrupt change in the main pancreatic 
duct (MPD) calibre with distal pancreatic atrophy and the signal intensity of lesion-to-spinal cord ratio on MRI; 
a significant difference was observed in MPD size on EUS. Diagnostic performance assessments of the image sets 
did not differ significantly between the blinded radiologists.
Conclusions: The clinical utility of non-enhanced EUS may be attributive in evaluating IPMN that has already been 
evaluated by non-enhanced MRI.
Key words: magnetic resonance imaging, endoscopic ultrasonography, intraductal papillary mucinous neoplasm of 
the pancreas.
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Introduction
Most cystic lesions of the pancreas are incidentally detect-
ed during ultrasonography, computed tomography (CT), 
or magnetic resonance imaging (MRI) combined with 
MR cholangiopancreatography (MRCP) performed be-
cause of an unrelated indication. Intraductal papillary mu-
cinous neoplasm of the pancreas (IPMN) is a fairly com-
mon cystic lesion of the pancreas, particularly observed 
in the elderly. IPMN was first recognised in the 1980s; 
the volume of published literature related to IPMN has in-
creased over the last decade alongside a sharp increase in 
incidence because of increased detection of such lesions. 
Asymptomatic cysts, most of which were presumably 
small IPMNs, were identified in 2.8% of 2832 consecutive 
CT scans performed in one year at a single institution [1]. 
IPMNs are defined as grossly visible intraductal epithelial 
neoplasms with papillary proliferation and cyst formation 
[2]. The 2010 World Health Organisation (WHO) classi-
fication subcategorises the IPMNs according to their ma-
lignant transformation as IPMN with low or intermediate 
dysplasia, IPMN with high-grade dysplasia (equivalent to 
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the intraductal papillary mucinous carcinoma [IPMC], 
non-invasive), and IPMN with an associated invasive 
carcinoma (IPMC). In addition to pancreatic intraepi-
thelial neoplasia (PanIN), the most common neoplastic 
precursor to ductal pancreatic cancer is IPMN [2,3]. Its 
relatively slow growth enables early diagnosis and curative 
surgical treatment [4]. IPMC has been attracting attention 
as a potentially curable pancreatic cancer if treated prior 
to becoming invasive. 
Diffusion-weighted imaging (DWI) has been shown to 
be effective in the diagnosis of malignant IPMN [5-7]. Ma-
lignant pancreatic tumours generally show higher signal in-
tensities and lower apparent diffusion coefficients (ADCs) 
than benign tumors [8]. The diagnostic performance of 
DWI was shown to be comparable to that of contrast-en-
hanced MRI for evaluating the malignant potential of cystic 
pancreatic lesions [7,9]. Furthermore, the combined use of 
DWI and MRCP with non-enhanced MRI was shown to be 
particularly effective in the diagnosis of malignant IPMN 
and prediction of invasive IPMC risk [5,7].
Endoscopic ultrasonography (EUS) is the best modality 
for monitoring pancreatic cystic neoplasms and for predict-
ing the malignant potential of branch-type IPMN through 
the detection and evaluation of mural nodules [10,11]. The 
diameter and width of the mural nodules of papillary pro-
trusions as assessed on preoperative EUS were shown to re-
liably distinguish between low- and high-risk IPMNs [12].
In situations in which there is an increased detection 
of IPMNs due to widespread use of imaging examinations, 
differentiating benign from potentially malignant ones using 
a noninvasive technique is of great value. In the screening 
test, the administration of contrast material is not neces-
sary. For evaluating the malignant potential of IPMN us-
ing non-enhanced MRI combined with MRCP and DWI, 
the advantage of using non-enhanced EUS to supplement 
non-enhanced MRI is not clear. The minimal interobserv-
er variability of assessing mural nodules or solid tumours 
would be invaluable for the administration of appropriate 
treatment in patients with suspicious lesions [5]. To our 
knowledge, the added value of non-enhanced EUS to the in-
terpretation of findings from non-enhanced MRI combined 
with MRCP and DWI has not been investigated to date.
The purpose of our study was to evaluate the diagnostic 
value of combined use of non-enhanced MRI with MRCP 
and DWI and non-enhanced EUS (hereafter referred to as 
MRI with EUS), as opposed to non-enhanced MRI with 
MRCP and DWI alone (hereafter referred to as MRI alone).
Material and methods
Patients
The requirement for written, informed consent from pa-
tients was waived because of the retrospective nature of 
the review of clinical and imaging data. Patients who were 
suspected to have IPMN with malignant potential upon 
preoperative MRI and/or EUS and who underwent cura-
tive surgery for IPMN at our institution between June 01, 
2009 and October 31, 2015 were retrospectively identi-
fied by searching our imaging database. Preoperative EUS 
with fine needle aspiration had never been performed 
in our institution. The following exclusion criteria were 
used: (a) patients with pancreatic ductal adenocarcinoma 
concomitant with IPMNs, characterised by distinct cyst-
ic lesions on histopathology; (b) patients with mucinous 
carcinoma on histopathology; (c) patients who did not 
undergo MRI or EUS; and (d) patients who did not un-
dergo preoperative MRI and EUS within the immediate 
six months before the date of surgery. A detailed process 
of the patient selection is summarised in Figure 1.
–  Patients who were suspected of having IPMN with malignant potential upon preoperative MRI and/or EUS 
–  Patients who underwent curative surgery for IPMN at our institution between June 01, 2009 and October 31, 2015 
n = 50 
Exclusion 
–  Patients with pancreatic ductal adenocarcinoma concomi-
tant with IPMNs characterized by distinct cystic lesions on 
histopathology 
n = 4 
–  Patients with mucinous carcinoma on histopathology  
n = 3 
–  Patients who did not undergo MRI or EUS 
n = 3 
–  Patients who did not undergo preoperative MRI and EUS 
within the immediate 6 months before the date of surgery  
n = 2 
Eligible for current study 
n = 38 
Branch-type IPMN 
n = 19 
Mixed-type IPMN 
n = 12 
MPD-type IPMN 
n = 7 
Figure 1. Flow diagram shows the process for patient selection
IPMN – intraductal papillary mucinous neoplasms, MRI – magnetic resonance imaging, EUS – endoscopic ultrasonography, MPD – main pancreatic duct
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Magnetic resonance imaging technique
All patients had undergone MRI on a 1.5 Tesla unit 
(MAGNETOM Avanto or Symphony, Siemens Medical 
Solutions, Erlangen, Germany) using a phased-array body 
coil. Non-enhanced fat-suppressed in-phase T1-weighted 
breath-hold spoiled gradient-recalled-echo (GRE) imag-
es, T2-weighted fast-spin-echo (T2W-FSE) images, DW 
images with low and high b-values (b = 50, 800 s/mm2, 
respectively), and 3D-fat-suppressed T1-weighted GRE 
sequences with Cartesian sampling, named volumetric 
interpolated breath-hold examination (VIBE), on Siemens 
Healthcare MRI systems were obtained in the axial plane. 
Half-Fourier acquisition single-shot turbo spin-echo 
(HASTE) sequence was obtained in the axial and coronal 
planes. A respiratory-triggered 3D-T2-weighted MRCP 
sequence was acquired, and coronal maximum intensity 
projection (MIP) was reconstructed based on a dataset. 
We have included DWI as a routine protocol for MRCP 
conducted at our institution. Details of imaging param-
eters evaluated in this study are summarised in Supple-
mentary Table 1.
Endoscopic ultrasonography technique
After obtaining written, informed consent, patients were 
sedated with midazolam using an intravenous bolus dose 
of 4-5 mg under haemodynamic and oximetric monitor-
ing. EUS was performed by an endosonographer with 
20 years of experience at our institution. An electronic ra-
dial (GF-UE260, Olympus Medical Systems, Tokyo, Japan) 
or a curved linear array echoendoscope (GF-UCT260, 
Olympus Medical Systems, Tokyo, Japan) with the Pro-
Sound Alpha-10 processor (Hitachi-Aloka Medical Co., 
Ltd., Tokyo, Japan) was used for endoscopic diagnosis. 
Tissue harmonic EUS screening of the pancreaticobiliary 
system was performed using standardised imaging tech-
niques [13,14]; particular attention was paid to primary 
pancreatic lesions. Harmonic imaging was achieved with 
a transmitting frequency of 3.75 MHz and receiving fre-
quency of 7.5 MHz. The acoustic power of harmonic EUS 
was set with a mechanical index of 0.25-0.3, and a single fo-
cus point was set at the most distant margin of the pancre-
atic lesions from the transducer. During EUS examination, 
tumour locations were recorded (head, body, and tail or 
diffuse). The cyst sizes and the thicknesses of cyst wall and/
or septum and mural nodules were measured. The associ-
ated presence of main pancreatic duct dilatation and/or an 
invasive cystic lesion component was recorded, if identified.
Image analysis
Evaluation of imaging findings for preliminary analyses
One radiologist with 15 years of MRI experience retro-
spectively reviewed the patient medical records at our in-
stitution. The same radiologist, who was aware of the clin-
ical information, evaluated both the interpreted MR and 
EUS findings on a picture archiving and communication 
systems (PACS) monitor. According to the 2012 interna-
tional consensus/Fukuoka guidelines (Fukuoka guidelines 
[FG]) for the management of IPMN and mucinous cyst-
ic neoplasms of the pancreas, which focus on high-risk 
stigmata (HRS) and worrisome imaging features (WFs) 
[10] the following morphological findings were assessed 
by the same radiologist: main pancreatic duct (MPD) size 
(> 10 mm or 5-9 mm); cyst size (> 30 mm or not); wall 
and/or septal thickness of cyst (> 3 mm or not); mural 
nodule height and/or width (> 10 mm, 5-9 mm or less); 
abrupt change in the MPD calibre with distal pancreatic 
atrophy (present or absent); and lymphadenopathy (pres-
ent or absent). In addition to performing an assessment 
according to the FG criteria, the quantitative assessment 
of ADC value based on the ADC map, and the calculation 
of lesion-to-spinal cord ratio (LSR) as a relative ADC val-
ue were performed. Optimal cut-off values of ADC and 
LSR were identified on receiver-operating-characteristic 
(ROC) curve analysis. These optimal cut-off values of 
ADC and LSR were applied for blinded evaluation.
An electronic calliper included in the PACS program 
was used for the measurement of the largest diameter of 
lesions in any axial or coronal image. For cyst size and wall 
and/or septal thickness of cyst, the parameters of evaluation 
were branch-type and mixed-type IPMN. If several cysts 
were present, the cyst with the largest wall and/or septal 
thickness was accepted as a lesion. A mural nodule was 
defined as any solid nodule in the MPD or branch duct 
of a well-circumscribed tissue lesion surrounded by a duct 
wall. For lymphadenopathy, a diameter > 10 mm in the 
short axis was accepted as significant lymphade nopathy.
Measurement of apparent diffusion coefficient and lesion-
to-spinal cord ratio on diffusion-weighted images
For the visual assessment of DW images, the ADC meas-
urements were performed on ADC maps included in the 
PACS program. The region of interest (ROI) for obtaining 
the ADC value was manually selected. In the case of a sol-
id component such as a mural nodule, thickened septa 
and/or cyst wall, or parenchymal mass, the ROI was se-
lected to cover both the solid and the cystic portions as 
much as possible. For precise measurement of ADC val-
ues, the ROI was placed on the lesion of the HASTE im-
age and was copied manually to the DW image to exclude 
a partial volume phenomenon. The mean ADC value 
calculated from at least three measurements was used in 
the analysis. T2W-FSE images were not used to determine 
a ROI because of their lower spatial resolution compared 
with that of HASTE images. 
LSR was measured on the DW image with a diffusion 
gradient of b = 800 s/mm2. For measurement of spinal 
cord signal intensity on DWI, the ROI was located on 
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Table 1. Imaging findings in patients with intraductal papillary mucinous carcinomas (IPMC) and intraductal papillary mucinous adenomas (IPMAs)
A) MRI
Factor IPMC
(n = 20)
IPMA
(n = 18)
Univariate Multivariate
p value OR 95% CI p value
Age, mean (SD) 73.9 (8.3) 68.1 (9.7) 0.6 – – –
Sex (male, female) 16, 4 12, 6 0.23 – – –
IPMN type – – < 0.001 – – –
Branch 4 15 – – – –
Mixed 9 3 – – – –
MPD 7 0 – – – –
Location – – 0.36 – – –
Head 14 10 – – – –
Body 5 4 – – – –
Tail 1 4 – – – –
MPD size (mm) – – – 5.02 0.61-41.4 0.13
≥ 10 8 0 0.004 – – –
≥ 5 17 5 < 0.001 – – –
Cyst size (mm) – – 0.45 – – –
≥ 30 7 13 – – – –
< 30 6 5 – – – –
Wall and/or septal thickness of cyst (mm) – – 0.1 – – –
≥ 3 6 3 – – – –
< 3 6 15 – – – –
Mural nodule height and/or width (mm)
≥ 10 3 1 0.35 – – –
≥ 5 11 7 0.32 – – –
Abrupt change in MPD calibre with distal pancreatic atrophy – – < 0.001 34.5 1.85-644 0.018
Present 13 1 – – – –
Absent 7 17 – – – –
Lymphadenopathy – – 0.99 – – –
Present 1 0 – – – –
Absent 19 18 – – – –
ADC value (× 10–3 mm2/s) 1.79 (± 0.45) 2.43 (± 0.33) < 0.001 – – –
Area of ROI for ADC (mm2) 734 (± 693) 798 (± 793) 0.62 – – –
LSR 0.26 (± 0.09) 0.17 (± 0.04) < 0.001 16.3 1.45-184 0.02
Area of ROI for LSR 91.8 (± 12.1) 84.5 (± 11.4) 0.08 – – –
B) EUS
IPMC
(n = 20)
IPMA
(n = 18)
Univariate Multivariate
p value OR 95% CI p value
MPD size (mm) – – < 0.001 8.15 1.04-63.9 0.045
≥ 10 9 0 – – – –
≥ 5 15 4 – – – –
Cyst size (mm) – – 0.27 – – –
≥ 30 5 11 – – – –
< 30 8 6 – – – –
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a slice of the lumbar enlargement because of its larger sig-
nal intensity compared with those of other regions of the 
spine, which facilitated location of the ROI. 
LSR was calculated according to the following formula:
LSR = mean signal intensity of lesion on DWI/maxi-
mum signal intensity of spinal cord on DWI. 
Blinded evaluation
For comparison of the diagnostic performance of MRI 
with EUS and MRI alone in distinguishing malignant from 
benign IPMNs, three radiologists (15, 8, and 7 years of 
experience in interpreting MR images, respectively) who 
were blinded to clinical and histopathological information, 
reviewed the image sets, i.e. preoperative MRI alone and 
MRI with EUS. Each image set was reviewed in the same 
order (first, MRI only; second, MRI with EUS) by three 
blinded readers to assess the following: MPD size (> 10 mm 
or 5-9 mm or not); cyst size (> 30 mm or not); wall and/
or septal thickness of cyst (> 3 mm or not); mural nodule 
height and/or width (> 10 mm or 5-9 mm or not); abrupt 
change in the MPD calibre with or without distal pancreat-
ic atrophy (present or absent); lymphadenopathy (present 
or absent); areas of restricted diffusion (present or absent); 
and signal alteration of pancreatic parenchyma and/or peri-
pancreatic fat tissue (present or absent). 
Restricted diffusion was defined by DWI findings 
that satisfied the following two conditions: (i) for qual-
itative assessment, when both high-signal intensity re-
gions compared with normal pancreas parenchyma on 
the high b value DWIs (b-value = 800 s/mm2) and low 
signal intensity regions on the ADC map with high LSR 
was detected; (ii) for quantitative assessment, the optimal 
cut-off LSR value determined on ROC curve analysis was 
used to determine the presence or absence of restricted 
diffusion. To evaluate the diagnostic values of other MR 
findings suggestive of IPMC with an invasive component, 
the presence of signal alteration in the pancreatic paren-
chyma or peripancreatic fat tissue was also evaluated. 
The readers were finally asked to evaluate the possibility 
of malignancy using the following previously reported 
scoring criteria [15,16]: score 1, no WFs or HRS; score 2, 
one WF with no HRS; score 3, more than two WFs with 
no HRS; score 4, one HRS; and score 5, more than two 
HRS. Radiological WFs included cyst size, wall and/or 
septal thickness of cyst; mural nodule without a restricted 
diffusion, abrupt change in the MPD calibre with distal 
pancreatic atrophy, and lymphadenopathy. Radiological 
HRSs included cystic lesion of the pancreatic head with 
dilatation of the biliary tract, mural nodule with a re-
stricted diffusion, and MPD dilatation > 10 mm. A mural 
nodule with a restricted diffusion was defined as equiva-
lent to an enhanced mural nodule. In the blinded reading 
of MRI with EUS, the written results of EUS were pro-
vided to each reader after the first reading of MRI alone. 
The EUS findings included findings associated with inter-
national consensus guidelines 2012 for the management 
of IPMN and MCN of the pancreas [10]. No blood flow 
information of the lesion was included. The MRI findings 
that changed according to the results of the EUS findings 
were recorded. Subsequently, each reader was asked to 
report a final decision by using the EUS results. At this 
point, the readers were asked to prioritise the EUS find-
ings, if required. 
Table 1. cont.
IPMC
(n = 20)
IPMA
(n = 18)
Univariate Multivariate
p value OR 95% CI p value
Wall and/or septal thickness of cyst (mm) – – 0.02 0.7 0.07-6.74 0.76
≥ 3 8 4 – – – –
< 3 3 14 – – – –
Mural nodule height and/or width (mm) – – 0.02 15.7 0.58-428 0.102
≥ 10 8 1 – – – –
≥ 5 13 7 – – – –
Abrupt change in the MPD calibre with distal pancreatic atrophy – – 0.001 6.43 0.53-77.8 0.14
Present 11 1 – – – –
Absent 9 17 – – – –
Lymphadenopathy – – 0.99 – – –
Present 0 0 – – – –
Absent 20 18 – – – –
MRI – magnetic resonance imaging, OR – odds ratio, CI – confidence interval, MPD – main pancreatic duct, ADC – apparent diffusion coefficient, LSR – lesion-to-spine ratio, EUS – endoscopic 
ultrasonography, IPMN – intraductal papillary mucinous neoplasm, ROI – region of interest  
Prior to statistical analysis, an f-test was applied to age, ADC values, area of ROI for ADC, LSR and the area of ROI for LSR to test for a normal distribution. All variables showed no significant 
difference except for LSR at the 5% significance level. Therefore, the Wilcoxon rank sum test was used for LSR.
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Histopathological analysis
In the present study, low- and intermediate-grade dyspla-
sia were defined as IPMN adenomas (IPMAs), whereas 
high-grade dysplasia and IPMN with carcinoma were de-
fined as IPMCs, as previously described [15].
Statistical analysis
All statistical analyses were performed using Ekuseru- 
Toukei 2015 (SSRI, Tokyo, Japan) and R (The R Project for 
Statistical Computing, www.r-project.org, version 3.3.0) 
software. 
For preliminary univariate analyses, a two-tailed paired 
t-test was used to compare the mean age, ADC, the area 
of ROI for ADC, and the area of ROI for LSR between the 
benign and malignant lesions. For LSR, the Wilcoxon rank 
sum test was used. Other findings were analysed using 
the Fisher exact test in the univariate analyses. A p value 
< 0.05 was considered statistically significant. Multivari-
ate logistic regression analyses were conducted with back-
ward selection using variables that showed a significant 
association on univariate analyses, and by referring to 
significant findings reported elsewhere [10,17,18]. 
Based on the blinded scores, an ROC curve was fit 
to each reader’s confidence rating using maximum-like-
lihood estimation to determine observer performance 
and cut-off values. Observer performance was individu-
ally calculated based on the area under the ROC curve 
(AUC). For assessment of the diagnostic performance of 
MRI with and without EUS and the prediction of invasive 
IPMC in the blinded evaluation, the sensitivity, specifici-
ty, positive-predictive value, and negative-predictive value 
were also determined for each reader. The assessment of 
each reader’s findings with and without information of 
EUS findings was performed using the McNemar test. 
To determine the agreement rate of scoring among the 
three blinded readers, weighted κ statistics was used to 
measure the degree of agreement respectively. A value of 
≤ 0.20 was considered as slight agreement, 0.21-0.40 as 
fair agreement, 0.41-0.60 as moderate agreement, 0.61-
0.80 as substantial agreement, and ≥ 0.81 as almost perfect 
agreement.
Ethical approval
This study was approved by the institutional review board 
of The Jikei University School of Medicine (approval num-
ber 28-160).
Results
The study included 38 patients with 20 histopathologically 
confirmed IPMC lesions and 18 IPMA lesions. The IPMC 
lesions included two with high-grade dysplasia, six with 
non-invasive carcinoma, and 12 with invasive carcinoma.
Evaluation of imaging findings for preliminary analyses
Findings of patients with IPMCs and IPMAs are shown 
in Table 1. On univariate analyses of MRI findings, sta-
tistically significant findings for the discrimination of 
malignant lesions from benign lesions were MPD size 
(≥ 5 mm), abrupt change in the MPD calibre with distal 
pancreatic atrophy, ADC value, and LSR (all p < 0.001). 
On multivariate analyses of MRI findings, both abrupt 
change in the MPD calibre with distal pancreatic atro-
phy and LSR demonstrated a statistically significant dif-
ference (odds ratio [OR]: 34.5; 95% confidence interval 
[CI]: 1.85-644; p = 0.018; OR: 16.3; 95% CI: 1.45-184; 
p = 0.02, respectively).
On univariate analyses of EUS findings, statistically 
significant findings for the discrimination of malignant 
lesions from benign lesions were MPD size (≥ 5 mm), 
Wall and/or septal thickness of cyst, Mural nodule height 
and/or width, and abrupt change in the MPD calibre with 
distal pancreatic atrophy (all p < 0.05). On multivariate 
analyses of EUS findings, only MPD size (≥ 5 mm) exhib-
ited a statistically significant difference (OR: 8.15; 95% CI: 
1.04-63.9; p = 0.045).
Measurement of apparent diffusion coefficient and 
lesion-to-spinal cord ratio using diffusion-weighted 
images
ADC values and LSR in DW images are shown in Figure 2. 
The cut-off ADC value for the diagnosis of IPMC was 
≤ 2.12 × 10−3 mm2/s. The cut-off LSR value for the diag-
nosis of IPMC was ≥ 0.18. The mean ADC for IPMC was 
significantly lower than that for IPMA (p < 0.001). On 
the other hand, the mean LSR for IPMC was significantly 
higher than that for IPMA (p < 0.001).
Blinded evaluation
The diagnostic performance of MRI with and without 
EUS in distinguishing malignant IPMNs from benign 
IPMNs using blinded evaluation is shown in Table 2. The 
three blinded readers showed no significant difference in 
AUCs for MRI alone and MRI with EUS (reader 1: 95% 
CI: −0.083-0.027; p = 0.32; reader 2: 95% CI: −0.034-
0.012; p = 0.34; reader 3: 95% CI: −0.121-0.025; p = 0.2). 
No significant difference was observed in the sensitivity, 
specificity, and positive- and negative-predictive values of 
MRI alone and MRI with EUS. There were differences be-
tween the three readers with respect to findings of mural 
nodule, wall and/or septal thickness of cyst, and MPD size 
(Figure 3). However, the difference was not statistically 
significant (mural nodule: p = 0.25 to > 0.99; wall and/
or septal thickness of cyst: p > 0.99; MPD size: p = 0.25). 
The prediction of invasive IPMC is shown in Table 3. 
The three readers generally showed lower sensitivity 
and higher specificity irrespective of the presence or ab-
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Figure 2. Apparent diffusion coefficient (ADC) and lesion-to-spinal cord ratio on diffusion-weighted imaging. Mean ADC for intraductal papillary mucinous 
adenocarcinoma (IPMC) was significantly lower than that for intraductal papillary mucinous adenoma (IPMA). The mean lesion-to-spinal cord ratio (LSR) 
for IPMC was significantly higher than that for IPMA
DWI – diffusion-weighted imaging
ADC value
IPMC IPMCIPMA IPMA
< 0.001
< 0.001
LSR
3.5
3
2.5
2
1.5
1
0.5
0
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
A B
sence of EUS information. The interobserver agreement 
between the three blinded readers is shown in Table 4. 
A moderate to substantial agreement was observed for 
the prediction of malignant IPMNs (κ = 0.57-0.79). MRI 
with EUS generally demonstrated higher interobserver 
agreement than MRI alone for the prediction of malig-
nant IPMNs. The same tendency was not observed for the 
prediction of invasive IPMCs (κ = 0.43-0.68) (Figure 4).
Discussion
In the present retrospective study, we compared the diag-
nostic performance of non-enhanced MRI with non-en-
hanced EUS to that of non-enhanced MRI alone for pre-
dicting the malignant potential of IPMNs, by performing 
a blinded evaluation. Combined use of non-enhanced 
MRI and EUS improved the ability to diagnose malignant 
IPMNs; however, this improvement was not statistically 
significant. The effectiveness of measuring ADC values 
and LSR for predicting malignant potential has been as-
sessed in previous reports [5,8,9,19,20]. Our finding that 
the ADC values of high-grade/invasive IPMN lesions 
were significantly lower than those of low-grade IPMN 
lesions is consistent with the findings of earlier studies 
[5,9]. The use of LSR in the present study also helped dis-
tinguish malignant from benign IPMNs; similar findings 
have been reported elsewhere in the context of lung can-
cer and gall bladder [19,20]. It is relatively convenient to 
calculate LSR on a PACS monitor independent of the MRI 
device. However, further studies are required to clarify the 
Table 2. Diagnostic performance of magnetic resonance imaging (MRI) with and without use of endoscopic ultrasonography (EUS), in distinguishing 
malignant from benign intraductal papillary mucinous neoplasms on blinded evaluation
AUC Sensitivity Specificity PPV NPV
MRI alone MRI with EUS p-value MRI 
alone
MRI 
with 
EUS
MRI 
alone
MRI 
with 
EUS
MRI 
alone
MRI 
with 
EUS
MRI 
alone
MRI 
with 
EUS
Reader1 0.75
(0.598-0.908)
0.78
(0.632-0.929)
0.32
(−0.083-0.027)
72.2 72.2 75.0 80.0 72.2 76.5 75.0 76.2
Reader2 0.71
(0.08-0.554)
0.72
(0.57-0.87)
0.34
(−0.034-0.012)
55.6 55.6 80.0 80.0 71.4 71.4 66.7 66.7
Reader3 0.63
(0.422-0.828)
0.67
(0.473-0.873)
0.2
(−0.121-0.025)
75 75 69.2 69.2 52.9 52.9 85.7 85.7
Sensitivity, specificity, PPV, and NPV values are expressed as percentages.  
Data in parentheses are 95% confidence intervals.
PPV – positive-predictive value, NPV – negative-predictive value, AUC – area under the ROC curve
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Table 3. Prediction of invasive intraductal papillary mucinous adenocarcinoma 
Sensitivity Specificity PPV NPV
MRI alone MRI with EUS MRI alone MRI with EUS MRI alone MRI with EUS MRI alone MRI with EUS
Reader 1 50.0 58.3 92.0 92.3 75.0 77.8 80.0 82.8
Reader 2 58.3 66.7 96.2 96.2 87.5 88.9 83.3 86.2
Reader 3 25.0 25.0 100 100 100 100 74.3 74.3
All parameters expressed as percentages.  
PPV – positive-predictive value, NPV – negative-predictive value, MRI – magnetic resonance imaging, EUS – endoscopic ultrasonography
Figure 3. A 51-year-old woman with intraductal papillary mucinous ade-
nocarcinoma with invasive lesion in the body of pancreas. Maximum in-
tensity projection image showing cystic lesion with multi-septal structures 
(arrow) (A). Half-Fourier acquisition single-shot turbo spin echo coronal 
image showing cystic lesion with multi-septal structures (B). Invasive le-
sion could not be detected on non-enhanced magnetic resonance images; 
Non-enhanced endoscopic ultrasonography image showing a cystic lesion 
with detection of both mural nodule and invasive lesion (arrow) (C)
A
C
B
Table 4. Weighted κ values of interobserver agreement between the three blinded readers 
Prediction of malignant IPMN Prediction of invasive IPMC
MRI alone MRI with EUS MRI alone MRI with EUS
Reader 1 and 2 0.67 (0.498-0.842) 0.67 (0.473-0.861) 0.68 (0.395-0.971) 0.62 (0.321-0.922)
Reader 2 and 3 0.57 (0.33-0.818) 0.65 (0.433-0.866) 0.48 (0.127-0.846) 0.43 (0.09-0.776)
Reader 1 and 3 0.72 (0.565-0.877) 0.79 (0.648-0.929) 0.49 (0.127-0.846) 0.49 (0.127–0.846)
κ-values with 95% Confidence Intervals are presented.
IPMN – intraductal papillary mucinous neoplasms, IPMC – intraductal papillary mucinous adenocarcinoma, MRI – magnetic resonance imaging, EUS – endoscopic ultrasonography
utility of LSR vis-à-vis that of ADC. Our study suggested 
a tendency for lower sensitivity and higher specificity for 
predicting malignant potential of IPMNs and invasive IP-
MCs on blinded evaluation. This suggests that evaluation 
of a score of 2 and 3 that includes one WF or more than 
two WFs with no HRS could impact the sensitivity. It has 
been previously shown that radiological WFs are not cu-
mulative in risk prediction because there is no stepwise 
increase in rates of malignant or invasive IPMN with an 
increase in the number of WFs [21]. 
In the blinded evaluation, the addition of EUS find-
ings changed the interpretation of mural nodule, wall and/
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or septal thickness of cyst, and MPD size on MRI by the 
three readers. However, the change was statistically insig-
nificant. Non-enhanced MRI with DWI has only a limited 
value for diagnosis of high-grade dysplasia and stage T1 
carcinoma [7]. The low prevalence of a solid proliferative 
portion in both non-invasive IPMC and benign IPMN 
was reported to underlie the significant overlap of ADC 
values between these two lesions [5]. Furthermore, de-
pending on the viscosity of the contents of cystic lesions 
and/or mucus plugs, the ADC values and LSR of lesions 
can show various values. From this perspective, assess-
ment of vascularity for solid proliferative portion may 
be necessary. On the basis of the FG criteria that accord 
weight to an enhancing mural nodule for the purpose of 
determining malignancy [10], our findings suggest that 
blood flow information is necessary for the interpretation 
of WFs, especially for mural nodules and wall and/or sep-
tal thickness of cyst.
Diagnostic accuracy study demonstrated that the FG 
criteria, which was selected in our study, has higher sen-
sitivity in detecting high-grade dysplasia and cancer com-
pared to the two guidelines created by the 2015 American 
Gastroenterological Association and the American College 
of Radiology [22].
A
C D
B
Figure 4. An 82-year-old man with intraductal papillary mucinous adenocarcinoma with invasive lesion in the head of pancreas. Multilocular cystic 
mass with mural nodules was detected on non-enhanced magnetic resonance imaging. An invasive lesion with restricted diffusion was detected on 
diffusion-weighted image (arrow) (A). Restricted diffusion was identified as a low-signal lesion on apparent diffusion coefficient map (arrow) (B). 
The uncinate process of pancreas showed loss of normal morphology due to invasive lesion of the intraductal papillary mucinous adenocarcinoma on 
T2-weighted image (arrow) (C). A multilocular cystic mass with mural nodules (arrow) was detected by endoscopic ultrasonography, which failed to 
identify the invasive lesion (D)
As stated in the FG criteria, if we were able to add the 
EUS findings with blood flow data of the lesion, when eval-
uating the non-enhanced MRI findings, the sensitivity of 
our results could have been improved, especially in cases 
that scored 2 or 3 on blinded evaluation. 
Contrast-enhanced harmonic EUS with time - intensity 
curve analysis was shown to be useful for quantitative eval-
uation of blood flow in the IPMN microvasculature, and for 
differentiating between high-grade dysplasia/invasive car-
cinoma and low- and intermediate-grade dysplasia [23]. In 
clinical practice, although a non-enhanced EUS as a screen-
ing modality can detect pancreatic intraepithelial neoplasia 
lesions and small invasive carcinomas associated with IPMN 
[24,25] in the case of lesions scored as 2 or 3, it is reasonable 
to recommend enhanced EUS in addition to non-enhanced 
MRI. Presently, there is no consensus on the use of dynamic 
contrast enhanced MRI for distinguishing malignant from 
benign IPMNs. Further studies are required to assess the 
relative value of enhanced MRI and enhanced EUS.
Several limitations of the present study should be 
acknowledged. The retrospective study design and rela-
tively small sample size are key limitations that limit the 
statistical power of the analysis and may have introduced 
an element of selection bias. In particular, changes in FG 
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(2012) might have influenced the patient inclusion crite-
ria. Secondly, in some cases it was difficult to distinguish 
mural nodule from mucous plug or normal pancreatic 
parenchyma in the preliminary analyses. This may have 
influenced the interpretation of MRI findings in the blind-
ed evaluation. Thirdly, the EUS criteria for IPMNs were 
mainly the MPD and internal characteristics of the cystic 
lesion; there was inadequate emphasis on the presence or 
absence of findings suggestive of IPMC with an invasive 
component. This could have had an impact on the two 
readers with lower κ values for MRI with EUS than for 
MRI alone, in the prediction of invasive IPMC.
In conclusion, the clinical utility of non-enhanced 
EUS may be attributive in evaluating IPMN that has al-
ready been evaluated by non-enhanced MRI. The results 
of our analysis suggest that the additional use of enhanced 
EUS for patients with one WF or more than two WFs and 
no HRS on non-enhanced MRI may be useful.
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Supplementary Table 1. Pulse sequence parameters for 1.5-Tesla MR imaging  
  FS GRE-T1WI T2WI DWI RARE FS 3D VIBE HASTE 3D-MRCP True FISP
TR (ms) 102-142 3000 1200-1500 4500 4.94-5.20 584-600 1050-1400 320-333.1
TE (ms) 4.76-5.04 90-91 67-86 758-759 1.86-1.93 180 601-614 1.41-1.52
FA (degrees) 70 150 180 15.0 110-160 140-150 77
b values 50/800
Matrix 187 × 256 208 × 320-256 × 
× 320
77 × 128 307 × 384 199 × 384 141 × 256-176 × 
× 256
314 × 320-323 × 
× 320
205 × 256
FOV 308 × 380-308 × 
× 384
308 × 380 262 × 350-277 × 
× 370
300 × 300 300 × 400 275 × 400 320 × 320-340 × 
× 340
400 × 400
ST (mm) 7.0 7.0 7.0 70 3.0 4.0 1.8 4.0
BW (Hz/pixel) 300 601 1346-2298 150 260 781 488 543-651
AT (s) 38 30 2:09-2:26 4.5 19-20 20 1:59-2:07 19-120
ETL 31 307 141-176 87-117
FS – fat suppressed; GRE-T1WI – gradient-echoT1-weighted imaging; T2WI – T2-weighted imaging; DWI – diffusion-weighted imaging; HASTE – half-Fourier acquisition single-shot turbo spin 
echo; MRCP – MR cholangiopancreatography; VIBE – volumetric interpolated breath-hold examination (T1-weighted GRE sequences with cartesian sampling which is referred to as “VIBE” on 
Siemens Healthcare MRI systems); TR – repetition time; TE – echo time; FA – flip angle; FOV – field of view; ST – slice thickness; BW – bandwidth; AT – acquisition time; ETL – echo train length
